指南与共识创伤与烧伤复苏、休克与脓毒症

创伤复苏中接受RhD阳性低效价O型全血及红细胞的RhD阴性育龄女性输血后管理:美国外科医师学会创伤委员会等联合立场声明与资源文件

Posttransfusion Management of RhD-Negative Females of Childbearing Potential Who Receive RhD-Positive Low-Titer Group O Whole Blood and RBCs During Trauma Resuscitation: A Joint Position Statement and Resource Document of the American College of Surgeons Committee on Trauma, Prehospital Blood Transfusion Coalition, National Association of Emergency Medical Services Physicians, Trauma Hemostasis an
指南 / 共识 · J Am Coll Surg · 2026-07-22
一句话结论RhD阴性育龄女性创伤大出血时,若无RhD阴性血且输血临床指征明确,不应因未来生殖风险而扣留RhD阳性血制品,生存优先。

该联合立场声明由美国外科医师学会创伤委员会、院前输血联盟、全国急救医师协会、创伤止血与氧合研究网络及Allo Hope基金会共同制定,针对创伤复苏中接受RhD阳性低效价O型全血或红细胞的RhD阴性育龄女性。多学科专家组复习文献、登记数据、建模研究及伦理考量后形成共识:RhD阳性血制品在无RhD阴性血且输血指征明确时不应被扣留;推荐对低容量暴露进行选择性Rh免疫球蛋白预防、结构化抗体监测、患者咨询、多学科随访及机构流程。建模估计抗D介导的胎儿新生儿溶血病围产期死亡风险约0.04%,严重HDFN与围产期死亡合计风险约0.24%。

要点

  • RhD阴性育龄女性创伤大出血时,若无RhD阴性血且输血临床指征明确,专家组结论为不应扣留RhD阳性血制品,即刻生存优先于未来生殖风险。
  • 创伤输血后D同种免疫发生率报告范围约8%至43%。
  • 建模估计RhD阳性输血后抗D介导HDFN的围产期死亡风险约0.04%,严重HDFN与围产期死亡合计风险约0.24%。
  • 估计任何HDFN并发症的未来妊娠风险范围约0.6%至6.5%。
  • 推荐管理包括对低容量暴露的选择性Rh免疫球蛋白预防、结构化抗体监测、患者咨询、多学科随访及机构流程。

适用人群与场景

  • 创伤复苏中接受RhD阳性低效价O型全血或红细胞的RhD阴性育龄女性。

处置流程与药物剂量

  • 推荐管理包括对低容量暴露的选择性Rh免疫球蛋白预防、结构化抗体监测、患者咨询、多学科随访及机构流程。

研究设计与关键结果

  • 该文件为多学科专家组联合立场声明与资源文件,专家组代表创伤外科、输血医学、急诊医学、重症医学、产科、儿科及院前急救,复习现有文献、登记数据、建模研究、现有指南及伦理考量,通过迭代过程形成共识推荐。
  • 创伤输血后报告D同种免疫发生率范围约8%至43%。
  • 建模研究估计RhD阳性输血后抗D介导的胎儿新生儿溶血病围产期死亡风险约0.04%,严重HDFN与围产期死亡合计风险约0.24%。
  • 估计任何HDFN并发症的未来妊娠风险范围约0.6%至6.5%。
  • 专家组结论:当无RhD阴性血制品且输血临床指征明确时,不应扣留RhD阳性血制品。

证据类型、等级与局限

  • 证据类型:多学科专家组联合立场声明与资源文件,基于文献、登记数据、建模研究、现有指南及伦理考量的共识推荐。

对床旁实践的改变

  • 对RhD阴性育龄女性创伤大出血,若无RhD阴性血且输血临床指征明确,不应因未来生殖风险而延迟或扣留RhD阳性血制品,即刻生存优先。
  • 推荐对接受RhD阳性血制品的RhD阴性育龄女性实施选择性Rh免疫球蛋白预防(针对低容量暴露)、结构化抗体监测、患者咨询、多学科随访及机构流程。

指南或共识出处

  • Posttransfusion Management of RhD-Negative Females of Childbearing Potential Who Receive RhD-Positive Low-Titer Group O Whole Blood and RBCs During Trauma Resuscitation: A Joint Position Statement and Resource Document of the American College of Surgeons Committee on Trauma, Prehospital Blood Transfusion Coalition, National Association of Emergency Medical Services Physicians, Trauma Hemostasis an

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Increasing use of low-titer group O whole blood and red blood cells in trauma resuscitation has increased the likelihood that RhD-negative females of childbearing potential (FCPs) will receive RhD-positive blood products. Concurrently, national trauma data demonstrate that FCPs with traumatic hemorrhage are approximately 40% less likely to receive low-titer group O whole blood than comparable males, highlighting a trauma systems and equity concern. Evidence-based guidance for post-transfusion management remains limited.

STUDY DESIGN: A multidisciplinary panel representing trauma surgery, transfusion medicine, emergency medicine, critical care, obstetrics, pediatrics, and prehospital care reviewed available literature, registry data, modeling studies, existing guidance, and ethical considerations and developed consensus recommendations through an iterative process for management of RhD-negative FCPs exposed to RhD-positive blood products during trauma resuscitation.

RESULTS: Reported D-alloimmunization rates following trauma transfusion range from approximately 8%-43%. Modeling studies estimate a perinatal death risk from anti-D-mediated hemolytic disease of the fetus and newborn (HDFN) of approximately 0.04% and a combined severe HDFN/perinatal death risk of approximately 0.24% after RhD-positive transfusion. Estimated risk of any HDFN-complicated future pregnancy ranges from approximately 0.6%-6.5%. The panel concluded that RhD-positive blood products should not be withheld when RhD-negative products are unavailable and transfusion is clinically indicated. Recommended management includes selective Rh immunoglobulin prophylaxis for low-volume exposures, structured antibody surveillance, patient counseling, multidisciplinary follow-up, and institutional protocols.

CONCLUSIONS: For RhD-negative FCPs with life-threatening hemorrhage, immediate survival should take precedence over potential future reproductive risk. Standardized post-transfusion pathways may support equitable access to life-saving transfusion while mitigating alloimmunization-related reproductive risks.

来源:J Am Coll Surg,查看原文。版权归原作者所有。

参考来源

  1. Henry R, Coleman JR, Holcomb JB, et al. Post-Transfusion Management of RhD-Negative Females of Childbearing Potential Who Receive RhD-Positive Low-Titer Group O Whole Blood and Red Blood Cells During Trauma Resuscitation: A Joint Position Statement and Resource Document of the American College of Surgeons Committee on Trauma (ACS-COT), Prehospital Blood Transfusion Coalition (PBTC), National Association of Emergency Medical Services Physicians (NAEMSP), Trauma Hemostasis and Oxygenation Research (THOR) Network, and Allo Hope Foundation (AHF). J Am Coll Surg. 2026. PMID: 42490058. doi:10.1097/XCS.0000000000002099

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。